- Job Type: Full-Time
- Function: Accounting/Finance
- Industry: Vaccine
- Post Date: 03/15/2023
- Website: www.vaxcyte.com
- Company Address: 353 Hatch Drive, Foster City, CA, 94404
- Salary Range: $142,000 - $162,000
About Vaxcyte
High-fidelity vaccines against pneumococcal infection and other bacterial infectionsJob Description
Vaxcyte, Inc. (Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease (IPD). The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 150 employees and anticipates continued, significant growth. Following the October 2022 follow-on equity offering, which generated approximately $651 million in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24. On October 24, 2022, the Company announced positive topline safety, tolerability and immunogenicity data from the Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64. The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children. VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD. Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-XP, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease. We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.
Summary:
Vaxcyte is seeking a highly energetic and self-motivated individual to join our growing Finance Team. The Equity Administration Manager is responsible for all aspects of equity and stock administration. The ideal candidate is one who has a can-do attitude, a customer-centric approach to his or her work with vigor and determination and has demonstrated the ability to deliver results in a high-growth environment. In addition, we are looking for a candidate who is flexible and has a passion for innovation and improvement in processes. A successful candidate is one who has great attention to detail but does not lose sight of the big picture.
Essential Functions:
- Process/administer all of the company’s equity programs (Equity Incentive Plans and ESPP), maintain daily recordkeeping and ensure that transactions are correctly processed and settled in a timely manner.
- Maintain equity database integrity and ensure accuracy of record keeping.
- Manage all equity transactions, including but not limited to new equity awards and distribution of online grant agreements, stock option exercises, cancellations and forfeitures, potential future restricted stock units and awards, potential future performance-based grants, contributions, distributions and purchases for ESPP.
- Manage open enrollment process for ESPP.
- Ensure proper tax and reporting is complete and accurate for all equity transactions.
- Prepare monthly, quarterly and annual reconciliations of records between Stock Administration and General Ledger, HR, Payroll, transfer agent, etc.
- Coordinate between external and internal partners on 10b5-1 plans and SEC filings (Section 16-related Forms 3, 4, and 5). Prepare tables and disclosures for the proxy statement and annual 10-K and quarterly10-Qs.
- Perform quarterly and annual ISO disqualifying disposition reporting.
- Prepare and distribute year-end tax statements for all equity transactions.
- Prepare slides related to equity for Compensation Committee meetings.
- Serve as liaison between HR, Legal, transfer agent and stock administration service providers for all equity plan and stockholder related matters.
- Partner with Legal in managing trade clearances and trading windows.
- Prepare all month-end close journal entries and reconciliations related to Equity.
- Automate and improve processes for stock administration for scalability.
- Maintain compliance with all company policies and procedures, including SOX controls, and all federal, state and local payroll tax laws.
- Perform equity SOX controls and participate in walk through and control testing.
- Prepare schedules for external audits and various other regulatory audits (401K, Workers’ Compensation, etc.).
- Provide employee education and respond to inquiries and requests regarding stock matters.
- Assist with providing various equity-related reports for accounting, tax and audit purposes.
- Assist with special projects as needed, including ERP and other accounting-related implementations and upgrades.
Requirements:
- Degree in Accounting or equivalent experience.
- Minimum 3 years of stock administration experience with Certified Equity Professional (CEP)preferred; public company experience required.
- Knowledge and experience preparing and filing Forms 3, 4 and 5 and preparing information for proxy statement and other regulatory reporting.
- Experience with U.S. federal and state taxation relating to equity compensation and general knowledge of global taxation of equity compensation.
- Extensive skills and experience in working on and maintaining data integrity in Equity Edge on-Line (EEO).
- Strong Excel skills.
- Ability to manage multiple tasks under strict deadlines with meticulous attention to detail.
- Positive work ethic and organizational skills with a high attention to detail and unquestionable integrity and personal ethics.
- A collaborative team player with the ability to partner with internal and external contacts at all levels and provide exceptional customer service.
- Ability to work independently and as a part of a team, shift focus and adapt to changing priorities.
- Ability to manage highly confidential information with professionalism and unquestionable integrity.
- Demonstrated ability to thrive in a dynamic and fast-paced environment.
- Exceptional written and verbal communication skills with proven ability to effectively communicate complex stock plan matters to employees at all levels.
- All Vaxcyte employees require vaccination against COVID-19.
Reports to: Sr. Director, Controller
Location: San Carlos, CA
Compensation:
The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $142,000 - $162,000